Immunoproliferative Disorders |
| Active, not recruiting | 3 | 4420 | Europe | Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) | University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen | Multiple Myeloma | 12/21 | 12/22 | | |
|
|
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents |
|
|
| Recruiting | 3 | 1578 | Europe | pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1 | Assistance Publique - Hôpitaux de Paris, Shire | Acute Lymphoblastic Leukemia | 04/26 | 04/26 | | |
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients |
|
|
| Active, not recruiting | 2 | 140 | Europe | cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2 | Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories | Primary Central Nervous System Lymphoma | 05/16 | 05/26 | | |
| Recruiting | 2 | 34 | RoW | Ibrutinib-RICE, Imbruvica | Singapore General Hospital, Janssen, LP | Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent | 08/23 | 08/23 | | |
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma |
|
|
| Active, not recruiting | 1/2 | 56 | US | Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone | Cristina Gasparetto, Celgene | Multiple Myeloma | 12/16 | 01/25 | | |
NCT01999491: A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma |
|
|
| Active, not recruiting | 1 | 39 | US | NC-4016 | M.D. Anderson Cancer Center, NanoCarrier Co., Ltd. | Advanced Cancers, Lymphoma | 11/18 | 11/18 | | |
| No Longer Available | N/A | | US | Erwinia L-asparaginase, Erwinase | Phoenix Children's Hospital, Fisher Bioservices, Jazz Pharmaceuticals | Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia | | | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib |
|
|
| No Longer Available | N/A | | US | Carfilzomib | University of Arkansas, Onyx Therapeutics, Inc. | Multiple Myeloma | 04/15 | 04/15 | | |
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Elotuzumab, BMS-901608 | Sundar Jagannath, Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients |
|
|
| No Longer Available | N/A | | Canada | bortezomib, melphalan, prednisone | Janssen-Ortho Inc., Canada, Ortho Biotech Canada | Multiple Myeloma | | | | |
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Panobinostat | Novartis Pharmaceuticals | Multiple Myeloma | | | | |
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron | Dana-Farber Cancer Institute, Bristol-Myers Squibb | Multiple Myeloma in Relapse, Multiple Myeloma | | | | |
| Recruiting | N/A | 10 | US | 124I-PU-AD, PET Scan, Blood draws | Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc. | Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease | 04/18 | 08/18 | | |
EAP, NCT02197650: Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase |
|
|
| No Longer Available | N/A | | Europe | suspension of erythrocytes encapsulating L-asparaginase, GRASPA®, eryaspase | ERYtech Pharma | Acute Lymphoblastic Leukemia | | | | |